Practical Aspects of Pathogenetic Therapy for Gastroesophageal Reflux Disease

V.P. Shipulin


The article deals with gastroesophageal reflux disease (GERD). Currently, there is being investigated a large number of new drugs, which can improve the treatment of acid-related disea-ses, but the best acid-reducing drugs yet are proton pump inhibitors (PPIs). In connection with this, the issue what drugs from the IPPs group should be preferred was and remains relevant for practitioners. Given the low potential of drug interactions, pantoprazole may be considered the drug of choice for acid-reducing therapy, especially in elderly patients, usually taking quite a lot of drugs; as well as in patients using drugs with a narrow therapeutic window.


gastroesophageal reflux disease; treatment; proton pump inhibitors; pantoprazole


Bell N.J., Hunt R.H. Role of gastric acid suppression in the treatment of gastro-oesophageal reflux disease // Gut. — 1992. — 33. — 118.

Caestecker J. Prokinetics and reflux: a promise unfulfilled // Eur. J. Gastroenterol. Hepatol. — 2002. — № 14 (1). — Р. 5-7.

Chiba N., De Gara C.J., Wilkinson J.M., Hunt R.H. Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis // Gastroenterology. — 1997. — 112. — 1798.

Dent J., Kahrilas P.J., Hatlebakk J., Vakil N., Denison H., Franze´n S., Lundborg P. A randomized, comparative trial of a potassium competitive acid blocker (AZD0865) and esomeprazole for the treatment of patients with nonerosive reflux disease // Am. J. Gastroenterol. — 2008. — 103. — 20-26.

Donnellan C., Sharma N., Preston C., Moayyedi P. Medical treatments for the maintenance therapy of reflux oesophagitis and endoscopic negative refl ux disease // Cochrane Database Syst. Rev. — 2004. — 4. — CD003245.

Gedda K., Briving C., Svensson K., Maxvall I., Andersson K. Mechanism of action of AZD0865, a K+-competitive inhibitor of gastric H+,K+-ATPase // Biochem. Pharmacol. — 2007. — 73. — 198-205.

Guidance of the use of proton pump inhibitors in the treatment of dyspepsia: NICE, UK // Technology Apprasial Guidance. — 2000. — № 7.

Hampel H., Abraham N.S., El-Serag H.B. Meta-analysis: obesity and the risk for gastroesophageal reflux disease and its complications // Ann. Intern. Med. — 2005. — 143. — 199.

Hunt R.H. Importance of pH control in the management of GERD // Arch. Intern. Med. — 1999. — 159. — 649.

Kahrilas P.J., Fennerty M.B., Joelsson B. High-versus standard-dose ranitidine for control of heartburn in poorly responsive acid reflux disease: A prospective, controlled trial // Am. J. Gastroenterol. — 1999. — 94. — 92.

Kahrilas P.J., Shaheen N.J., Vaezi M. American Gastroenterological Association Medical Position Statement on the Management of Gastroesophageal Reflux Disease // Gastroenterology. — 2008. — 135. — 1383.

Kahrilas P.J., Shaheen N.J., Vaezi M.F. American Gastroenterological Association Institute technical review on the ma-nagement of gastroesophageal reflux disease // Gastroenterology. — 2008. — 135. — 1392.

Kaltenbach T., Crockett S., Gerson L.B. Are lifestyle measures effective in patients with gastroesophageal reflux disease? An evidence-based approach // Arch. Intern. Med. — 2006. — 166. — 965.

Katz P. et al. ACG Guidelines for the Diagnosis and Ma-nagement of Gastroesophageal Reflux Disease // Am. J. Gastroenterol. — 2013. — 108. — 308-328.

Marian S. McDonagh, Pharm D. Drug Class Review on Proton Pump Inhibitors Final Report // Oregon Evidence-based Practice Center, July 2006. — P. 96.

Scarpignato C., Pelosini I., Di Mario F. Acid suppression therapy: where do we go from here? // Recent Advances in Gastrointestinal Pharmacology and therapeutics. — 2006. — Р. 11-59.

Thomson ABR. Are the orally administered PPI equivalent? A comparison of lansoprasole, omeprasole, pantoprasole, and rabeprasole // Curr. Gasroenterol. Rep. — 2000. — 2. — 482-493.

Vakil N. et al. The Montreal Definition and Classification of Gastroesophageal Reflux Disease: A Global Evidence-Based Consensus // Am. J. Gastroenterol. — 2006. — № 10. — Р. 1900-1920.

Wedemeyer R.S., Blume H. Pharmacokinetic Drug Interaction Profiles of Proton Pump Inhibitors: An Update // Drug. Saf. — 2014. — 37. — 201-211.

Copyright (c) 2016 GASTROENTEROLOGY

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.


© Publishing House Zaslavsky, 1997-2018


   Seo анализ сайта